Brief: Adocia Announces Positive Topline Data From Study Of Biochaperone
Jan 25 (Reuters) - Adocia Sa ADOC.PA :
* ADOCIA ANNOUNCES POSITIVE TOPLINE DATA FROM A
DOSE-PROPORTIONALITY STUDY OF BIOCHAPERONE COMBO IN PEOPLE WITH
TYPE 2 DIABETES
* ADOCIA SA - STUDY CONFIRMED PREVIOUS RESULTS THAT
BIOCHAPERONE
COMBO ACTS SIGNIFICANTLY FASTER AND LASTS SIGNIFICANTLY LONGER
THAN HUMALOGMIX
* ADOCIA SA - ALL TREATMENTS WERE WELL TOLERATED
* ADOCIA SA - BOTH PRIMARY ENDPOINTS WERE MET IN STUDY
Source text for Eikon: ID:nBw3FxjpNa
Further company coverage: ADOC.PA
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Adocia SA
See all newsFrench biopharma firm Adocia H1 revenue drops on weaker feasibility study income
Brief: Adocia H1 Operating Income EUR -7.947 Million
Brief: Adocia Says Sanofi’S Exclusive Right For Partnership Agreement For Development Of M1Pram Has Expired
Brief: Adocia And Vester Finance Sign Shareholder Loan Agreement
Brief: Adocia Sees Challenges With GLP-1, Amylin & Other Metabolic Peptides